Neuroleptic malignant syndrome: Further lessons from a case report

Psychosomatics

Volumn 51, Issue 4, 2010, Pages 349-354

  Casamassima, Francesco ^a   Lattanzi, Lorenzo ^a   Perlis, Roy H ^a   Litta, Antonella ^a   Fui, Erika ^a   Bonuccelli, Ubaldo ^a   Fricchione, Gregory ^a   Cassano, Giovanni B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIPYRETIC AGENT; BROMOCRIPTINE; DIAZEPAM; DOPAMINE RECEPTOR STIMULATING AGENT; ELECTROLYTE; HALOPERIDOL; LORAZEPAM; ANALGESIC AGENT; ANTIINFECTIVE AGENT; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BIPOLAR DISORDER; BLOOD PRESSURE REGULATION; CASE REPORT; CATATONIA; CLINICAL FEATURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; ELECTROCONVULSIVE THERAPY; FEMALE; HUMAN; NEUROLEPTIC MALIGNANT SYNDROME; REHYDRATION; TREATMENT INDICATION; TREATMENT OUTCOME; CHEMICALLY INDUCED; COMPLICATION; FLUID THERAPY; FOLLOW UP; PROCEDURES;

ADULT; ANALGESICS, NON-NARCOTIC; ANTI-BACTERIAL AGENTS; ANTICOAGULANTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BROMOCRIPTINE; CATATONIA; DIAZEPAM; DOPAMINE AGONISTS; ELECTROCONVULSIVE THERAPY; ELECTROLYTES; FEMALE; FLUID THERAPY; FOLLOW-UP STUDIES; GABA MODULATORS; HALOPERIDOL; HUMANS; LORAZEPAM; NEUROLEPTIC MALIGNANT SYNDROME; TREATMENT OUTCOME;

EID: 77955590524     PISSN: 00333182     EISSN: 15457206     Source Type: Journal    
DOI: 10.1176/appi.psy.51.4.349     Document Type: Article

References (56)

1. Delay J, Pichot P, Lemperiere T, et al: [A non-phenothiazine and non-reserpine major neuroleptic, haloperidol, in the treatment of psychoses]. Ann Med Psychol (Paris) 1960; 118:145-152
2. Caroff SN, Mann SC: Neuroleptic malignant syndrome. Med Clin North Am 1993; 77:185-202
3. Stubner S, Rustenbeck E, Grohmann R, et al: Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry 2004; 37(suppl 1):S54-S64 (Pubitemid 38658331)
4. Strawn JR, Keck PE Jr, Caroff SN: Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164:870-876
5. Nisijima K, Ishiguro T: Cerebrospinal fluid levels of monoamine metabolites and gamma-aminobutyric acid in neuroleptic malignant syndrome. J Psychiatr Res 1995; 29:233-244
6. Ueda M, Hamamoto M, Nagayama H, et al: Biochemical alterations during medication withdrawal in Parkinson's disease with and without neuroleptic malignant-like syndrome. J Neurol Neurosurg Psychiatry 2001; 71:111-113 (Pubitemid 32591951)
7. Keck PE Jr, Pope HG Jr, Cohen BM, et al: Risk factors for neuroleptic malignant syndrome: a case-control study. Arch Gen Psychiatry 1989; 46:914-918 (Pubitemid 19259539)
8. Berardi D, Amore M, Keck PE Jr, et al: Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatry 1998; 44:748-754 (Pubitemid 28496791)
9. White DA, Robins AH: Catatonia: harbinger of the neuroleptic malignant syndrome. Br J Psychiatry 1991; 158:419-421
10. Koch M, Chandragiri S, Rizvi S, et al: Catatonic signs in neuroleptic malignant syndrome. Compr Psychiatry 2000; 41:73-75 (Pubitemid 30051772)
11. Paparrigopoulos T, Tzavellas E, Ferentinos P, et al: Catatonia as a risk factor for the development of neuroleptic malignant syndrome: report of a case following treatment with clozapine. World J Biol Psychiatry 2007; 10:1-4
12. Levenson JL: Neuroleptic malignant syndrome. Am J Psychiatry 1985; 142:1137-1145
13. Rothke S, Bush D: Neuropsychological sequelae of neuroleptic malignant syndrome. Biol Psychiatry 1986; 21:838-841 (Pubitemid 16044008)
14. Caroff SN, Mann SC, Keck PE Jr, et al: Residual catatonic state following neuroleptic malignant syndrome. J Clin Psychopharmacol 2000; 20:257-259 (Pubitemid 30202371)
15. Benjelloun G, Jehel L, Abgrall G, et al: [Acute catatonic syndrome after neuroleptic malignant syndrome]. Encephale 2005; 31(6; Pt 1):705-709
16. Lattanzi L, Mungai F, Romano A, et al: Subcutaneous apomorphine for neuroleptic malignant syndrome. Am J Psychiatry 2006; 163:1450-1451 (Pubitemid 44464425)
17. Ghaziuddin M, Quinlan P, Ghaziuddin N: Catatonia in autism: a distinct subtype? J Intellect Disabil Res 2005; 49(Pt 1):102-105
18. Northoff G: Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiology. J Neural Transm 2002; 109: 1453-1467 (Pubitemid 36061257)
19. Berry N, Sagar R, Tripathi BM: Catatonia and other psychiatric symptoms with vitamin B12 deficiency. Acta Psychiatr Scand 2003; 108:156-159
20. Taylor MA, Fink M: Catatonia in psychiatric classification: a home of its own. Am J Psychiatry 2003; 160:1233-1241
21. Carroll BT: Kahlbaum's catatonia revisited. Psychiatry Clin Neurosci 2001; 55:431-436
22. Bell LV: On a form of disease resembling some advanced stages of mania and fever. Am J Insanity 1849; 6:97-127
23. Fricchione GL: Neuroleptic catatonia and its relationship to psychogenic catatonia. Biol Psychiatry 1985; 20:304-313
24. White DA: Catatonia and the neuroleptic malignant syndrome: a single entity? Br J Psychiatry 1992; 161:558-560
25. Carroll BT, Taylor RE: The non-dichotomy between lethal catatonia and neuroleptic malignant syndrome. J Clin Psychopharmacol 1997; 17:235-238
26. Fink M: Neuroleptic malignant syndrome and catatonia: one entity or two? Biol Psychiatry 1996; 39:1-4
27. Chandler JD: Psychogenic catatonia with elevated creatine kinase and autonomic hyperactivity. Can J Psychiatry 1991; 36: 530-532
28. Fink M, Taylor MA: The many varieties of catatonia. Eur Arch Psychiatry Clin Neurosci 2001; 251(suppl 1):I8-I13
29. Vancaester E, Santens P: Catatonia and neuroleptic malignant syndrome: two sides of a coin? Acta Neurol Belg 2007; 107: 47-50
30. Fricchione GL, Fozdar M, Francis A, et al: The recognition and treatment of the catatonic syndrome. J Intens Care Med 1997; 12:135-147
31. Gill J, Singh H, Nugent K: Acute lithium intoxication and neuroleptic malignant syndrome. Pharmacotherapy 2003; 23:811-815 (Pubitemid 36629085)
32. Ali S, Pearlman RL, Upadhyay A, et al: Neuroleptic malignant syndrome with aripiprazole and lithium: a case report. J Clin Psychopharmacol 2006; 26:434-436 (Pubitemid 44187651)
33. Berry N, Pradhan S, Sagar R, et al: Neuroleptic malignant syndrome in an adolescent receiving olanzapine-lithium combination therapy. Pharmacotherapy 2003; 23:255-259 (Pubitemid 36197467)
34. Takubo H, Harada T, Hashimoto T, et al: A collaborative study on the malignant syndrome in Parkinson's disease and related disorders. Parkinsonism Relat Disord 2003; 9(suppl 1):S31-S41 (Pubitemid 36539391)
35. Meagher LJ, McKay D, Herkes GK, et al: Parkinsonism-hyperpyrexia syndrome: the role of electroconvulsive therapy. J Clin Neurosci 2006; 13:857-859 (Pubitemid 44415487)
36. Newman EJ, Grosset DG, Kennedy PG: The parkinsonism-hyperpyrexia syndrome. Neurocrit Care 2009; 10:136-140
37. Fink M, Shorter E, Taylor MA: Catatonia is not schizophrenia: Kraepelin's error and the need to recognize catatonia as an independent syndrome in medical nomenclature. Schizophr Bull 2010; 36:314-320
38. Lee JW: Catatonic variants, hyperthermic extrapyramidal reactions, and subtypes of neuroleptic malignant syndrome. Ann Clin Psychiatry 2007; 19:9-16
39. Malur C, Pasol E, Francis A: ECT for prolonged catatonia. J ECT 2001; 17:55-59
40. Chung A, Varghese J: Treatment of catatonia with electroconvulsive therapy in an 11-year-old girl. Aust N Z J Psychiatry 2008; 42:251-253 (Pubitemid 351234196)
41. Esmaili T, Malek A: Electroconvulsive therapy (ECT) in a six-year- old girl suffering from major depressive disorder with catatonic features. Eur Child Adolesc Psychiatry 2007; 16:58-60 (Pubitemid 46648356)
42. Wilkins KM, Ostroff R, Tampi RR: Efficacy of electroconvulsive therapy in the treatment of nondepressed psychiatric illness in elderly patients: a review of the literature. J Geriatr Psychiatry Neurol 2008; 21:3-11 (Pubitemid 351260008)
43. Cupello A, Bandini F, Albano C, et al: Catatonic features in major depression relieved by electroconvulsive treatment: parallel evaluation of the status of platelet serotonin transporter. Int J Neurosci 2008; 118:1460-1466
44. Thirthalli J, Phutane VH, Muralidharan K, et al: Does catatonic schizophrenia improve faster with electroconvulsive therapy than other subtypes of schizophrenia? World J Biol Psychiatry 2009; 10:772-777
45. Maletzky BM: The first-line use of electroconvulsive therapy in major affective disorders. J ECT 2004; 20:112-117 (Pubitemid 38747573)
46. Ali S, Welch CA, Park LT, et al: Encephalitis and catatonia treated with ECT. Cogn Behav Neurol 2008; 21:46-51
47. Kaestner F, Mostert C, Behnken A, et al: Therapeutic strategies for catatonia in paraneoplastic encephalitis. World J Biol Psychiatry 2008; 9:236-240
48. Wang HY, Huang TL: Benzodiazepines in catatonia associated with systemic lupus erythematosus. Psychiatry Clin Neurosci 2006; 60:768-770 (Pubitemid 44736605)
49. Petrides G, Divadeenam KM, Bush G, et al: Synergism of lorazepam and electroconvulsive therapy in the treatment of catatonia. Biol Psychiatry 1997; 42:375-381 (Pubitemid 27380972)
50. Sakkas P, Davis JM, Janicak PG, et al: Drug treatment of the neuroleptic malignant syndrome. Psychopharmacol Bull 1991; 27:381-384
51. Rosenberg MR, Green M: Neuroleptic malignant syndrome: review of response to therapy. Arch Intern Med 1989; 149:1927-1931 (Pubitemid 19232210)
52. Trollor JN, Sachdev PS: Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry 1999; 33:650-659 (Pubitemid 29488160)
53. Ghaziuddin N, Alkhouri I, Champine D, et al: ECT treatment of malignant catatonia/NMS in an adolescent: a useful lesson in delayed diagnosis and treatment. J ECT 2002; 18:95-98 (Pubitemid 35012000)
54. Hayashi H, Aoshima T, Otani K: Malignant catatonia with severe bronchorrhea and its response to electroconvulsive therapy. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30:310-311 (Pubitemid 43288073)
55. Suzuki A, Kondo T, Otani K, et al: Association of the TaqI A polymorphism of the dopamine D2 receptor gene with predisposition to neuroleptic malignant syndrome. Am J Psychiatry 2001; 158:1714-1716 (Pubitemid 32923667)
56. Kishida I, Kawanishi C, Furuno T, et al: Association in Japanese patients between neuroleptic malignant syndrome and functional polymorphisms of the dopamine D2 receptor gene. Mol Psychiatry 2004; 9:293-298 (Pubitemid 38496721)